ClinicalTrials.govSep 28, 2026
A GLP-1 medicine is being tested against methamphetamine addiction
Researchers at the University of Texas Southwestern have completed a pilot study of tirzepatide in adults who have both obesity and moderate to severe methamphetamine use disorder. The study planned for up to 45 participants. Everyone received the medicine once a week for 32 weeks, prescribed for its approved weight use, with weekly clinic visits and a four-week follow-up. The phase 2 study had no comparison group; it was built to test whether such a trial is feasible and to look for early signs of an effect.
